ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals' subsidiary, Noumed Pharmaceuticals, renewed a 3-year OTC Medicines Supply Agreement with an Australian pharmacy chain, valued at approximately ₹204 Crore.
Sai Parenterals Ltd submitted its 25th Annual Report for FY 2025-26 to the stock exchanges as required under SEBI (LODR) regulations.
Sai Parenterals Limited has submitted the notice for its 25th Annual General Meeting, scheduled to be held on 10th September, 2026 via video conference.
Management is pivoting to acquisitions after regulatory shifts blocked organic expansion in Hyderabad. While revenue growth appears strong due to the Numed consolidation, margins were hurt by high logistics costs in Australia.
Sai Parenterals Limited will acquire a 60% stake in Prathyuk Laboratories Private Limited for ₹15 Crore. This strategic move secures an established R&D setup in the pharma sector.
Sai Parenterals Limited will acquire a 60% equity stake in Saicriti Pharma Private Limited for ₹83.83 Crore in cash.
Sai Parenterals is transitioning from a domestic-focused player to an export-driven CDMO/branded generic platform through major acquisitions and capacity expansion. Q1 FY27 presentation focuses on IPO proceeds variation and global accreditation strategy.
Sai Parenterals announced Q1 FY27 results, reporting standalone revenue of Rs. 56.2 crore. The company also announced acquisitions in Saicriti Pharma and Prathyak Laboratories.
Sai Parenterals Limited announced the appointment of Mr. Kunal Kakumanu as Executive Director, alongside the resignations of Mrs. Aruna Karusala and Ms. Shivali Aggarwal.
Sai Parenterals reported no deviation or variation in the utilization of IPO proceeds for the quarter ended June 30, 2026. This is a routine compliance filing.
Sai Parenterals Ltd reported revenue from operations of ₹178.7 Cr (+435.0% YoY) and net profit of ₹7.9 Cr (+464.3% YoY) for Q1 FY27.
Sai Parenterals has scheduled a board meeting for August 11, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Sai Parenterals Ltd submitted its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulatory requirements.
Sai Parenterals Ltd has submitted its quarterly shareholding pattern for the period ended June 30, 2026, as required by SEBI regulations.